10 Stocks Investors Dumped Fast

4. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta Therapeutics declined by 7.67 percent on Monday to close at $39.71 each as investors unloaded portfolios amid the generally cautious market environment, while waiting for concrete developments from the ongoing US-China trade negotiations.

Additionally, investors may have sold off positions following the previous day’s gains, boosted by Scotiabank’s rating upgrade for its stock to “outperform” from “sector perform” previously.

The upgrade represented a vote of confidence amid the stock’s 68-percent year-to-date drop, dented by safety concerns linked to the death of a young male from taking its Elevidys drug.

Additionally, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reported a disappointing earnings performance in the first quarter of the year, having swung to a net loss of $447.5 million from a $36.1 million net income in the same period last year, despite revenues jumping by 80 percent to $744.9 million from $413.5 million year-on-year.

Looking ahead, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) said it expects lower revenues for full-year 2025, at $2.3 billion to $2.6 billion versus the $2.9 billion to $3.1 billion as expected previously.